Peptides DB
Research-centric peptide and protocol reference hub
Study 32 of 32Mazdutide (IBI362) literatureInternational journal of molecular sciences · Review2023

From Oxyntomodulin to Retatrutide: A Translational Review of Metabolic Polyagonism.

The paper reviews the evolution of metabolic polyagonism and the potential of co-agonists like mazdutide but does not provide new clinical data to support its claims.

Read at International journal of molecular sciencesAdd to compare

Where it sits

this study against the rest of the mazdutide (ibi362) corpus
8
Preclinical
10
Observational
0
Open-label
4
Randomised
10
Reviews · this one

Summary and findings

This review discusses the development of engineered GLP-1R/GCGR co-agonists, including mazdutide, and their effects on metabolic parameters. It highlights the importance of GCGR signaling in various metabolic processes. The paper also examines the evolution of proglucagon-derived peptides and their pharmacological implications.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
2023

Abstract

The authors’ words, as International journal of molecular sciences supplied them

Oxyntomodulin (OXM), an endogenous proglucagon-derived peptide with dual glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) agonism, provides a physiological precedent for contemporary multi-receptor pharmacology. Recognition that GCGR signaling regulates not only hepatic glucose production but also amino acid turnover, lipid metabolism, substrate oxidation, and energy expenditure prompted the development of engineered GLP-1R/GCGR co-agonists, including cotadutide, mazdutide, survodutide, and pemvidutide. Retatrutide extends this strategy by integrating GIPR, GLP-1R, and GCGR agonism within a single long-acting peptide and has produced substantial improvements in body weight, glycemic control, and cardiometabolic parameters in phase 2 and phase 3 trials. This review examines the evolutionary and structural relationships of the proglucagon-Class B1 GPCR system, OXM biosynthesis and receptor pharmacology, the mechanistic rationale for therapeutic GCGR agonism, and the molecular and clinical development of dual and triple agonists. We further address receptor balance, the GIPR agonism-antagonism paradox, receptor-specific causal attribution, and the unresolved limitations of translating molecular pharmacology into durable clinical benefit. Finally, we propose an Activity-Exposure-Context framework for interpreting polyagonist pharmacology and discuss prospective enteroinsular phenotyping using standardized mixed-meal testing as a testable strategy to investigate interindividual variability in therapeutic response.

Background

The paper addresses the role of oxyntomodulin (OXM) as a proglucagon-derived peptide and its dual receptor agonism. Previous studies have indicated that GCGR signaling influences various metabolic processes, leading to the development of engineered co-agonists. This review is significant as it consolidates knowledge on the evolution and pharmacology of these peptides, which may inform future therapeutic strategies.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

The review synthesizes existing literature on metabolic polyagonism without presenting new data. While it discusses the potential of these peptides, the lack of specific findings limits the ability to draw definitive conclusions about their clinical significance. The review highlights the complexities of translating molecular pharmacology into clinical outcomes, suggesting that further research is necessary.

Key findings

  • Not reported in abstract.

Limitations

  • Not reported in abstract.

Elsewhere in the Mazdutide (IBI362) corpus

AEffects of Incretin-Based Pharmacotherapies on Lean Body Mass in Adults With Overweight, Obesity, or Type 2 Diabetes: A Systematic Review With Prespecified Network Meta-Analysis Feasibility Assessment.Cureus · 2023 · -8.3 percentage points relative change in lean body mass for pooled tirzepatide versus placebo (95% CI: -10.6 to -6.1)reviewBEffectiveness of the Dual GLP-1R/GCGR Agonist Mazdutide in GSD IXc: A Case Report.Journal of clinical medicine · 2023 · n=1 · 20.6% reduction in body weight from 85.0 to 67.5 kg after 4 months.HumanAEfficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial.The lancet. Diabetes & endocrinology · 2025 · n=179 · -18.1% bodyweight change with 16 mg mazdutide at 32 weeks, n=51, p<0.0001.HumanAEfficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis.Diabetes, obesity & metabolism · 2023 · -6.65 kg absolute body weight reduction, MD, moderate certainty.reviewDEfficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis.Diabetes, obesity & metabolism · 2026 · -6.65 kg absolute body weight reduction, MD, moderate certainty.reviewDTreatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: Research Summary.JAMA · 2026review